clinical dataBioNTech’s mRNA cancer vaccine misses Phase 2/3 endpointBioNTech’s BNT113, combined with Keytruda, failed to significantly improve progression-free survival in a Phase 2/3 head and neck cancer trial. The study will continue to assess whether the combination … more ➔
obesityZealand taps Generate’s AI discovery engine in $1.2B obesity dealZealand Pharma will pay Generate Biomedicines $30 million (€27 million) upfront to discover protein drugs for obesity and other metabolic diseases, broadening its pipeline beyond peptides and small … more ➔
Meanwhile in biotechLundbeck starts Phase 2; Rewind secures funding; Beactica picks a degraderBeyond the main headlines, European biotech kept moving this week. Lundbeck and Neurosterix advanced neurological drug programs, Rewind secured funding for myelin repair, and Beactica selected a cancer … more ➔
startupUndecimal raises $18M to take siRNA beyond the liverUndecimal Bio has launched with $18 million (about €16 million) in seed funding to develop delivery molecules that carry gene-silencing medicines beyond the liver, initially targeting kidney and vascular … more ➔
obesityRoche’s China shopping spree continues with $1B Rona obesity pactRoche has licensed worldwide rights to Rona Therapeutics’ experimental ALK7-targeting RNA interference therapy for obesity and metabolic diseases, offering up to $100 million (about €89 million) … more ➔
licensingEnodia lands $500M Pfizer deal to target proteins at the point of synthesisParis-based Enodia Therapeutics is entering a partnership with big pharma Pfizer to discover and develop small molecules for targeted protein degradation at the point of synthesis with a deal that could … more ➔
clinical dataElicera’s CAR-T clears detectable lymphoma in eight patientsSwedish biotech Elicera Therapeutics reported complete metabolic responses in eight of 12 patients treated with its experimental CAR-T therapy ELC-301 in the Phase 1 portion of its CARMA trial. Six remained … more ➔
startupDesentum secures €28M for faster allergy immunotherapyFinnish biotech Desentum has raised €28 million in an oversubscribed equity round to advance three allergy immunotherapy programs, with Phase 2 results for its lead birch pollen candidate expected … more ➔
autoimmune diseaseWhat’s next for argenx, Europe’s autoimmune breakthrough?Over the past few years, Belgium’s argenx has become a biotech force to be reckoned with, driven by the success of its autoimmune drug Vyvgart (efgartigimod alfa) in diseases such as generalised … more ➔
SchizophreniaNewron plans heart tests to lift schizophrenia trial holdItaly’s Newron Pharmaceuticals has disclosed that the FDA kept U.S. enrollment in a Phase 3 trial of its schizophrenia drug evenamide on hold, citing five deaths across all the drug’s clinical studies. … more ➔
